Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM

Investing.com -- Shares of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) rallied over 13% in Monday morning trading following a bullish initiation of coverage from Wall Street research firm Cantor Fitzgerald. The broker set an Overweight rating and an $8.00 price target on the biopharmaceutical company, reflecting substantial upside potential driven by the company’s ongoing late-stage cardiovascular research program.

Seedhouse expressed confidence in the mechanics of the trial, suggesting that broad precedent data and a strong mechanistic rationale point toward a successful outcome. Although commercialization of sotagliflozin, originally approved for heart failure under the brand name Inpefa, was previously deprioritized by the company, its pivot to HCM represents a potentially lucrative strategic shift.

Crucially, the firm emphasized that sotagliflozin operates through a mechanism completely orthogonal to cardiac myosin inhibitors (CMIs), the current mainstay of recent innovation in HCM treatment. Because background CMI therapy is permitted within the SONATA-HCM trial protocol, sotagliflozin is positioned to complement existing treatment regimens rather than compete directly against them.

Should the Phase 3 trial achieve its endpoints, Cantor Fitzgerald believes sotagliflozin will emerge "essentially unencumbered" competitively within an established multibillion-dollar treatment landscape. Against that backdrop, the $8.00 price target underscores an expectation of significant valuation expansion as the market increasingly prices in the asset's clinical probability of success ahead of early 2027.

Original Article

You May Also Be Interested In

• Lexicon drug shows cardiac and platelet effects in preclinical studies
• Mexico inflation accelerates in October, testing Banxico rate path
• Sterling today: Pound edges higher on U.S. tech drag